Avacta Group Plc (AVCT.L)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Christina Marie Coughlin B.S., M.D., Ph.D. | CEO, Interim Chief Medical Officer and Director | 53k | -- | 1970 |
| Mr. Brian M. Hahn | Chief Financial Officer | -- | -- | 1974 |
| Dr. Michelle Morrow Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Emma Wright | Group In-House Counsel | -- | -- | -- |
| Mr. Michael Vinegrad | Group Communications Director | -- | -- | -- |
| Mr. R. Craig Slater FCA | Chief Operating Officer of Diagnostics | 69k | -- | 1964 |
| Mr. David Wilson | Chief Commercial Officer of Diagnostics | -- | -- | -- |
| Ms. Karen Harrison | Chief Operating Officer of Therapeutics Division | -- | -- | -- |
| Ms. Anne McGurk | Joint Managing Director of Launch Diagnostics | -- | -- | -- |
| Dr. Simon Bennett BSc DPhil | Chief Business Officer of Therapeutics | -- | -- | -- |
Avacta Group Plc
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Avacta Group Plc engages in research and development activities within the therapeutics business, focusing on the development of cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, the rest of Europe, and internationally. The company operates through the Therapeutics segment. It provides its proprietary Affimer and pre|CISION technology platforms, which are used to deliver a portfolio of differentiated therapeutic and diagnostic products that address various markets. The company is developing AVA6000, a peptide drug conjugate form of doxorubicin, which is in Phase I clinical trials for treating locally advanced or metastatic solid tumors; AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor, directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100, which is designed to drive localization to FAP-expressing tumors, with the second Affimer domain binding albumin to improve pharmacokinetics by increasing plasma half-life. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer-based therapeutics. Avacta Group Plc was incorporated in 2003 and is headquartered in London, United Kingdom.
Corporate Governance
Upcoming Events
June 6, 2025 at 10:59 AM UTC
Avacta Group Plc Earnings Date
Recent Events
Recent Events Information Not Available